Duchenne Muscular Dystrophy

← Back to Class List

PDL Status Values

Y = preferred
N = non-preferred. Non-preferred drugs listed as N but without clinical drug use criteria are subject to the Non-Preferred Drugs in Select PDL Classes prior authorization criteria. New drugs will be listed as N until reviewed by the P&T Committee and are subject to the New Drug Policy.
V = voluntary non-preferred. Non-preferred mental health drugs are listed as V and prior authorization is not required.
Null (i.e. blank) = indicates the class or specific drug has not been reviewed for PDL placement.

To request a Prior Authorization, please use this form.

Generic Name Brand Name Form PDL
Status
Current Drug Use Criteria New Drug Evaluation
casimersen AMONDYS-45 VIAL PA Document Aug 05, 2021
deflazacort EMFLAZA ORAL SUSP PA Document  
deflazacort DEFLAZACORT TABLET PA Document  
deflazacort EMFLAZA TABLET PA Document Jul 27, 2017
delandistrogene moxeparvc-rokl ELEVIDYS KIT PA Document  
delandistrogene moxeparvc-rokl ELEVIDYS VIAL PA Document  
eteplirsen EXONDYS-51 VIAL PA Document Jul 27, 2017
golodirsen VYONDYS-53 VIAL PA Document  
vamorolone AGAMREE ORAL SUSP PA Document  
viltolarsen VILTEPSO VIAL PA Document